The Dermatology Digest

JULY 16, 2024

Whether it’s your first visit to the city or an annual tradition, SHADES at Edge offers a fresh, imaginative way to take in the 360 views of our iconic skyline like never before,” says Francesca Merlino, Chief Commercial Officer at Hudson Yards Experiences, in a news release.

Sun Protection 74

Sun Protection Partnerships Office Safety 74

Kim Gallo Esthetics

AUGUST 23, 2024

Additionally, PRP carries more health risks due to the requirement of an in-office blood draw, which poses potential risks of infection and cross-contamination. Effectiveness and Safety of Exosomes Exosomes have shown incredible potential in skin rejuvenation.

Microneedling 279

Microneedling Skincare Collagen Skin Health 279

The Dermatology Digest

MARCH 18, 2024

The Phase 3 clinical trials achieved all co-primary and secondary endpoints, and subjects completed the 16-week treatment with no significant safety issues.

Rosacea 74

Rosacea Medical Office Clinic 74

The Dermatology Digest

APRIL 18, 2024

The safety profile was similar across all three arms and overall, 88.9% of adverse events were rated as mild and no serious adverse events were identified. The study appears in the Aesthetic Surgery Journa l. “The The study appears in the Aesthetic Surgery Journa l.

Safety 36

Safety Office Surgery Dermatology 36

The Dermatology Digest

SEPTEMBER 20, 2024

Secondary efficacy objectives include progression-free survival, overall survival and local control up to twelve months after treatment, and the safety objective is the measurement of any related adverse events. Dr. Robert B.

Office 74

Office Safety Clinic Medical 74

The Dermatology Digest

FEBRUARY 22, 2024

The primary endpoints of the study are the proportion of SK lesions with a Physician Lesion Assessment (PLA) score of clear (PLA=0) at last visit and the safety of SM-020 gel 1.0% CT-213 is a Phase 2b randomized, double-blind, vehicle-controlled clinical trial in 60 subjects with five to ten SK target lesions treated with SM-020 gel 1.0%

Safety 36

Safety Clinic Office Hyperpigmentation 36

The Dermatology Digest

FEBRUARY 22, 2024

The primary endpoints of the study are the proportion of SK lesions with a Physician Lesion Assessment (PLA) score of clear (PLA=0) at last visit and the safety of SM-020 gel 1.0% CT-213 is a Phase 2b randomized, double-blind, vehicle-controlled clinical trial in 60 subjects with five to ten SK target lesions treated with SM-020 gel 1.0%

Safety 36

Safety Clinic Office Hyperpigmentation 36

The Dermatology Digest

JANUARY 5, 2024

“Verrica’s VP-315 program is designed to provide for the targeted delivery of an oncolytic peptide engineered to stimulate the patient’s immune system and destroy cancer cells,” says Ted White, Verrica’s President and Chief Executive Officer, in a news release.

Pharmaceutical 36

Pharmaceutical Safety Office Clinic 36

The Dermatology Digest

JUNE 10, 2024

With patients experiencing AK over larger surface areas, dermatologists are looking for ways to treat the entire affected area to help prevent further lesion progression,” saysKarl Ziegelbauer, Chief Scientific Officer at Almirall, in a news release.

Treatments 36

Treatments Safety Office Dermatology 36

The Dermatology Digest

SEPTEMBER 30, 2024

The OLE results continue to show that ESK-001 has the potential to safely and effectively inhibit the TYK2 target at the 40mg twice daily dose and deliver lasting benefits that improve over time with continued treatment,” says Dr. Jörn Drappa, Alumis’ Chief Medical Officer, in a news release.

Safety 36

Safety Clinic Sustainability Office 36

The Dermatology Digest

JANUARY 29, 2024

The STudy of Roflumilast foam Applied Topically for the redUction of seborrheic derMatitis (STRATUM) was a parallel group, double-blind, vehicle-controlled study evaluating the safety and efficacy of Zoryve (roflumilast) foam, 0.3% Zoryve foam was well-tolerated with a favorable safety and tolerability profile.

Dermatitis 74

Dermatitis Safety Dermatology Treatments 74

The Dermatology Digest

FEBRUARY 6, 2024

The sNDA is supported by two clinical phase I studies investigating the safety of the application of three tubes of Ameluz. Further to a Type A meeting with the FDA in 2021, an additional safety trial with 100 patients receiving PDT with three tubes of Ameluz was conducted. This data also formed part of the sNDA.

Safety 28

Safety Office Therapy Ingredients 28

The Dermatology Digest

MAY 16, 2024

Sonelokimab in PsA For PsA, Phase 3 initiation is anticipated in Q4 2024 following the announcement in March 2024 of the full dataset from the global Phase 2 ARGO trial (M1095-PSA-201) evaluating the efficacy and safety of the Nanobody sonelokimab over 24 weeks in patients with active PsA.

Safety 68

Safety Clinic Dermatology Office 68

Natural Beauty Med Spa

APRIL 28, 2024

However, you might be reluctant to commit to it due to concerns about safety. Safety is of the utmost importance to us, and we take every reasonable precaution to protect our patients. If you would like to learn more about us and how we may be able to help you look and feel amazing, contact our Dearborn office at 312-981-1291.

Med Spa 52

Med Spa Scarring Safety Makeup 52

The Dermatology Digest

FEBRUARY 14, 2024

The prevalence of atopic dermatitis, an extremely burdensome skin condition, continues to grow, and there is an increasing need for new, long-term, treatment options, especially for children,” says Todd Zavodnick, Chief Executive Officer of Dermavant, in a news release.

Dermatitis 74

Dermatitis Office Management Eczema 74

The Dermatology Digest

DECEMBER 14, 2023

Patients returned at week 16 to assess safety and evaluate maintenance response. Additionally, it can increase the time of use for biologics instead of switching between agents; therefore, decreasing overall healthcare costs and burden on patients and physician offices.” At week 12, patients stopped using the cream.

Injections 36

Injections Safety Office Therapy 36

The Dermatology Digest

JULY 22, 2024

“We are delighted at the launch of Uzpruvo in Europe and to be first-to-market,” adds Robert Wessman, Chief Executive Officer of Alvotech. This launch symbolizes the robustness of our platform, the value of our partnership with STADA, and our collective focus on the importance of biosimilars.”

Partnerships 36

Partnerships Pharmaceutical Marketing Office 36

Southeastern Esthetics Institute

AUGUST 23, 2016

Thorough organization of charting systems, patient and employee safety and sanitation practices, and consistent monitoring by supervisory staff is the key to medical spa success. A complete system must be in place per office, for the role of every action within the practice.

Esthetician 195

Esthetician Esthetics Document Office 195

The Dermatology Digest

APRIL 17, 2024

The randomized, double-blind, placebo-controlled, parallel group Phase 2 study is evaluating the efficacy and safety profile of multiple dose regimens of barzolvolimab in patients with CIndU who remain symptomatic despite antihistamine therapy, to determine the optimal dosing strategy.

Safety 36

Safety Injections Therapy Office 36

The Dermatology Digest

NOVEMBER 6, 2024

. “The new Translational Bridge Award addresses a critical gap in lupus research, enabling scientists to bring their most promising ideas closer to people living with lupus,” says Teodora Staeva, PhD, LRA Vice President and Chief Scientific Officer, in a news release.

Hospital 36

Hospital Therapy Management Networking 36

The Dermatology Digest

FEBRUARY 27, 2024

. “The approval of SIMLANDI marks the first high-concentration, citrate-free biosimilar to Humira with IC status,” says Dr. Eric Hughes, Executive Vice President Global R&D and Chief Medical Officer at Teva, in a news release.

Safety 36

Safety Marketing Pharmaceutical Partnerships 36

The Dermatology Digest

APRIL 23, 2024

The CRL did not identify any deficiencies related to the clinical efficacy or clinical safety data in the BLA, and the FDA did not request any new clinical trials or clinical data to support the approval of pz-cel. The BLA for pz-cel was accepted for filing and granted priority review designation by the FDA in November 2023.

Marketing 36

Marketing Safety Clinic Sustainability 36

The Dermatology Digest

AUGUST 21, 2024

The trial evaluated the efficacy and safety of TMB-001 in the treatment of congenital ichthyosis in patients (aged 6 or older) with either the autosomal recessive congenital ichthyosis (ARCI) or X-linked recessive ichthyosis (XLRI) subtypes.

Pharmaceutical 36

Pharmaceutical Clinic Office Safety 36

The Dermatology Digest

JANUARY 5, 2024

“Based on the data seen in our pivotal trials, DFD-29 could fundamentally improve the treatment paradigm for patients suffering from both inflammatory lesions and erythema (redness) from rosacea,” says Claude Maraoui, Co-Founder, President and Chief Executive Officer of Journey Medical, in a news release.

Rosacea 36

Rosacea Medical Office Safety 36

The Dermatology Digest

JANUARY 14, 2024

Zoryve foam was well-tolerated with a favorable safety and tolerability profile. As the first topical drug approved with a new mechanism of action for this condition in 20 years, foam represents an important advancement in treatment and addresses a truly significant need in this population.”

Dermatitis 72

Dermatitis Dermatology Office Safety 72

The Dermatology Digest

FEBRUARY 7, 2024

The total duration of the trial was up to 24 weeks, which included a four-week screening period, a 16-week treatment period and a four-week safety follow-up period. Improvements were also consistent across Patient Reported Outcomes through Week 16.

Safety 36

Safety Clinic Office Dermatology 36

The Dermatology Digest

MAY 6, 2024

The Phase 2a trial ( NCT05984784 ) evaluates the safety, pharmacokinetics, and efficacy of IMG-007 in adult patients with moderate-to-severe AD who had inadequate response to and/or intolerant of topical therapies. Key study endpoints include safety and percent change from baseline in eczema area and severity index (EASI) over time.

Safety 36

Safety Dermatitis Therapy Dermatology 36

The Dermatology Digest

JANUARY 20, 2024

The study is designed to assess the safety, tolerability, and pharmacokinetics, of orally administered EVO756. The Phase 1 study is a randomized, double-blind, placebo-controlled single and multiple ascending dose (SAD and MAD) study in normal healthy adults and an open-label study in adults with CSU.

Safety 36

Safety Office Dermatitis Dermatology 36

Les Nouvelles Esthetics & Spa

JANUARY 31, 2024

An interview with Lauren Becotte Rampello Lauren Becotte Rampello is the Founder and Chief Creative Officer of Pure Glow, premium airbrush tanning that mimics the skin’s natural tan. We invest heavily in their training, focusing on the intricacies of our products and safety protocols. What is your plan for company growth?

Branding 78

Branding Sales Office Safety 78

The Dermatology Digest

JANUARY 24, 2024

It is a phase 3, two-arm trial (N=513) that compares the efficacy and safety of delgocitinib cream with alitretinoin capsules. No specific treatment-emergent safety concerns were identified for delgocitinib cream, and the overall safety profile was consistent with what was observed in DELTA 1, 2 and 3.

Eczema 36

Eczema Safety Office Treatments 36

The Dermatology Digest

JANUARY 14, 2024

INTEGUMENT-1 and INTEGUMENT-2 (The INterventional Trial EvaluatinG roflUMilast cream for the treatmENt of aTopic dermatitis) were two identical Phase 3, parallel-group, double-blind, vehicle-controlled trials evaluating the safety and efficacy of roflumilast cream 0.15% in AD. Fully 91.5% Importantly, EASI-90 was observed in 22.4%

Dermatitis 36

Dermatitis Safety Dermatology Hospital 36

Art of Dermatology

MAY 17, 2024

At Art of Dermatology at the Laser and Skin Surgery Center of New York, patient safety and satisfaction is Dr. Jessica Krant’s primary concern. Making sure you are seeing a board-certified core cosmetic specialty physician (dermatologist, plastic surgeon, oculoplastic surgeon, or ENT facial plastic surgeon) in a real medical office is key.

Office 36

Office Surgery Safety Injections 36

The Dermatology Digest

JANUARY 16, 2024

and Sanofi), adding efficacy and safety data for people aged 12 years and older with atopic dermatitis (AD) and uncontrolled moderate-to-severe hand and/or foot involvement. Yancopoulos, MD, PhD, Board Co-Chair, President and Chief Scientific Officer at Regeneron, and a principal inventor of Dupixent, in a news release.

Dermatitis 36

Dermatitis Pharmaceutical Safety Dermatology 36

The Dermatology Digest

AUGUST 14, 2024

The Phase 2 trial is a 2-part, open-label, multicenter, dose-escalation, proof-of-concept study with a safety run-in designed to assess the safety and tolerability, pharmacokinetics, and efficacy of VP-315 when administered intratumorally to adults with biopsy-proven basal cell carcinoma. It’s very, very exciting data.”

Safety 36

Safety Pharmaceutical Clinic Dermatology 36

The Dermatology Digest

JANUARY 11, 2024

ADORING 1 and ADORING 2 were two identical, double-blind, randomized, vehicle-controlled Phase 3 studies that evaluated the efficacy and safety of Vtama cream, 1% in adults and pediatric patients down to 2 years old who had a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of 3 (moderate) to 4 (severe) at baseline.

Dermatitis 36

Dermatitis Safety Eczema Sensitive Skin 36

The Dermatology Digest

APRIL 22, 2024

Treatment was well-tolerated and no new safety signals were identified. Notably, in patients that previously had an inadequate response to dupilumab, two-thirds achieved EASI-90 and vIGA 0 or 1 when treated with eblasakimab,” says Dr Carl Firth, Chief Executive Officer of Aslan Pharmaceuticals, in a news release.

Pharmaceutical 36

Pharmaceutical Dermatitis Eczema Injections 36

The Dermatology Digest

JUNE 10, 2024

Two global, randomized, double blind, placebo-controlled trials are planned (IZAR-1 and IZAR-2) to evaluate the efficacy and safety of the nanobody sonelokimab over one year. Marketing Authorization Application.

Office 36

Office Safety Marketing Dermatology 36